Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Korro Bio (KRRO) EBITDA (2019 - 2025)

Historic EBITDA for Korro Bio (KRRO) over the last 7 years, with Q3 2025 value amounting to -$18.0 million.

  • Korro Bio's EBITDA rose 1184.58% to -$18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.8 million, marking a year-over-year decrease of 176.3%. This contributed to the annual value of -$83.3 million for FY2024, which is 263.76% down from last year.
  • As of Q3 2025, Korro Bio's EBITDA stood at -$18.0 million, which was up 1184.58% from -$25.9 million recorded in Q2 2025.
  • Korro Bio's 5-year EBITDA high stood at $5.8 million for Q4 2022, and its period low was -$25.9 million during Q2 2025.
  • Its 5-year average for EBITDA is -$19.8 million, with a median of -$20.4 million in 2024.
  • In the last 5 years, Korro Bio's EBITDA soared by 12719.23% in 2022 and then tumbled by 53786.16% in 2023.
  • Quarter analysis of 5 years shows Korro Bio's EBITDA stood at -$21.4 million in 2021, then surged by 127.19% to $5.8 million in 2022, then crashed by 537.86% to -$25.4 million in 2023, then grew by 15.44% to -$21.5 million in 2024, then rose by 16.19% to -$18.0 million in 2025.
  • Its last three reported values are -$18.0 million in Q3 2025, -$25.9 million for Q2 2025, and -$23.4 million during Q1 2025.